Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02361125 · ClinicalTrials.gov registry record · Phase 1
Patient Controlled Administration of Methylphenidate for Cancer Related Fatigue - PRN Methylphenidate
A Phase 1 study of Fatigue, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT02361125 is a Phase 1 study of Fatigue that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 31 participants, below the 218-participant average among 109 other Fatigue trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02361125, a Phase 1 study of Fatigue, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to evaluate the effectiveness of ritalin (methylphenidate) taken on an as needed basis for the management of cancer related fatigue. The effects of methylphenidate on pain, mood, and sedation will be evaluated. Researchers will also evaluate the level of fatigue throughout the day and any possible causes of fatigue.
Conditions Studied
Interventions
- DRUG Methylphenidate
- BEHAVIORAL Fatigue Evaluations
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2002-08-01 |
| Est. Completion | 2021-12-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02361125
The ClinicalTrials.gov registry entry for NCT02361125 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 109 other Fatigue trials with a reported enrollment target (86% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fatigue appearing as the primary indexed condition, and to 2 interventions - of which Methylphenidate is the first listed.
NCT02361125 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02361125 about?
NCT02361125 is a clinical study titled "Patient Controlled Administration of Methylphenidate for Cancer Related Fatigue - PRN Methylphenidate". The goal of this clinical research study is to evaluate the effectiveness of ritalin (methylphenidate) taken on an as needed basis for the management of cancer related fatigue. The effects of methylphenidate on pain, mood, and sedation will be evaluated. Researchers will also evaluate the level of f...
What is the current status of trial NCT02361125?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2002-08-01. Estimated completion is 2021-12-28.
What conditions does trial NCT02361125 study?
This clinical trial studies the following conditions: Fatigue.
What interventions are being tested in trial NCT02361125?
The interventions under investigation include: Methylphenidate (DRUG), Fatigue Evaluations (BEHAVIORAL).
Who is sponsoring clinical trial NCT02361125?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02361125 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fatigue
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized, Open-label, Safety Study of Subcutaneous and Intramuscular Injections of Niagen® Plus
RECRUITING · Phase 1
-
MitoQ for Fatigue in Multiple Sclerosis (MS)
ACTIVE NOT RECRUITING · Phase 1
-
Acupuncture to Treat Cancer-Related Fatigue in Breast Cancer Patients
COMPLETED · Phase 1
-
A Proof-of-Concept Trial on the Effect of Ketamine on Fatigue
COMPLETED · Phase 1
-
Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia
COMPLETED · Phase 1
-
Art and Surface Electromyography (EMG)
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.